Kołodziejska Renata, Tafelska-Kaczmarek Agnieszka, Pawluk Mateusz, Sergot Krzysztof, Pisarska Lucyna, Woźniak Alina, Pawluk Hanna
Department of Medical Biology and Biochemistry, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Karłowicza 24, 85-092 Bydgoszcz, Poland.
Department of Organic Chemistry, Faculty of Chemistry, Nicolaus Copernicus University, Gagarina 7, 87-100 Toruń, Poland.
Curr Issues Mol Biol. 2024 Jul 18;46(7):7668-7685. doi: 10.3390/cimb46070454.
The aim of this review is to provide experimental evidence for the programmed-death activity of Ashwagandha () in the anti-cancer therapy of breast cancer. The literature search was conducted using online electronic databases (Google Scholar, PubMed, Scopus). Collection schedule data for the review article covered the years 2004-2024. Ashwagandha active substances, especially Withaferin A (WA), are the most promising anti-cancer compounds. WS exerts its effect on breast cancer cells by inducing programmed cell death, especially apoptosis, at the molecular level. Ashwagandha has been found to possess a potential for treating breast cancer, especially estrogen receptor/progesterone receptor (ER/PR)-positive and triple-negative breast cancer.
本综述的目的是提供印度人参（）在乳腺癌抗癌治疗中程序性死亡活性的实验证据。使用在线电子数据库（谷歌学术、PubMed、Scopus）进行文献检索。综述文章的收集时间表数据涵盖2004年至2024年。印度人参的活性物质，尤其是沃替西汀A（WA），是最有前景的抗癌化合物。WS通过在分子水平上诱导程序性细胞死亡，尤其是细胞凋亡，对乳腺癌细胞发挥作用。已发现印度人参具有治疗乳腺癌的潜力，尤其是雌激素受体/孕激素受体（ER/PR）阳性和三阴性乳腺癌。
